Home > Name List By s > Sunitinib

CAS No 557795-19-4 , Sunitinib

  • Name: Sunitinib
  • Synonyms: Sunitinib intermediate; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)- (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4- dimethyl-; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;Sunitinib;SUNITINIB-D4; SUNITINIB BASE;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide;
  • CAS Registry Number:
  • Melting Point: 189-191 ºC
  • Flash Point: 299.8 ºC
  • Boiling Point: 572.1 ºC at 760 mmHg
  • Density: 1.229 g/cm3
  • Flash Point: 299.8 ºC
  • Molecular Weight: 398.47
  • InChI: InChI=1/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
  • Molecular Formula: C22H27FN4O2
  • Molecular Structure:CAS No:557795-19-4 Sunitinib
Search by region :

Select to

557795-19-4 Sunitinib base

  • China Nanjing Ange Pharmaceutical Co., Ltd. null
  • Fax: +86-25-86501191
  • Address: Room 2309-2311, Technical garden B place, Industrial university, NO.5 Xinmofang Road, Nanjing, China null,nullChina
Contact Supplier

557795-19-4 Sunitinib base

Contact Supplier

557795-19-4 Sunitinib

  • China Taizhou Creating Chemical Co.,Ltd [Manufacturers]
  • Tel: +86- 576- 88827176, 88828907
  • Fax: +86- 576- 88822496
  • Address: B Suite 12F,JiangbinBuilding,Jiaojiang,Taizhou,Zhejiang,China Taizhou,ZhejiangChina
Contact Supplier

557795-19-4 Sunitinib Malate

  • Sunitinib Malate, 98%+
  • China Olly Chem Co., Ltd [Manufacturers]
  • Tel: +86 24 6225 9849
  • Fax: +86 24 6225 9831
  • Address: Floor 5, Suite 501, Jiancai Building 44 Hepingbeida Street, Heping District, Shenyang Liaoning 110002, P R of China Shenyang,LiaoningChina
Contact Supplier

557795-19-4 Sunitinib

Contact Supplier

557795-19-4 Sunitinib

Contact Supplier

557795-19-4 Sunitinib

  • China Hangzhou Hysen Pharma [Importer/Exporter]
  • Tel: +86-571-89937383
  • Fax: +86-571-89937383
  • Address: No.808, B Building,Zijin Plaza, No.701,Gudun ROAD,Hangzhou CHINA-310012 HANGZHOU,ZHEJIANGChina
Contact Supplier

557795-19-4 Sunitinib

Contact Supplier

557795-19-4 Sunitinib

Contact Supplier

557795-19-4 Sunitinib

Contact Supplier

Select to

References of Sunitinib
Title: Sunitinib
CAS Registry Number: 557795-19-4
CAS Name: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Synonyms: 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
Molecular Formula: C22H27FN4O2
Molecular Weight: 398.47
Percent Composition: C 66.31%, H 6.83%, F 4.77%, N 14.06%, O 8.03%
Literature References: Tyrosine kinase inhibitor targeting VEGF-R2, PDGF-Rb, KIT and FLT3. Prepn: P. C. Tang et al., WO 0160814 (2001 to Sugen); eidem, US 6573293 (2003 to Sugen; Pharmacia & Upjohn); and kinase inhibition activity: L. Sun et al., J. Med. Chem. 46, 1116 (2003). Pharmacology: D. B. Mendel et al., Clin. Cancer Res. 9, 327 (2003). Clinical pharmacokinetics and evaluation in acute myeloid leukemia: A.-M. O'Farrell et al., ibid. 5465. LC-MS-MS determn in biological samples: S. Barattè et al., J. Chromatogr. A 1024, 87 (2004). Formulation development: A. Sistla et al., Drug Dev. Ind. Pharm. 30 19 (2004). Review of development and therapeutic potential: K. M. Sakamoto, Curr. Opin. Invest. Drugs 5, 1329-1339 (2004).
Properties: Orange solid. pKa 8.5. Log P (octanol/water): 3.1. Soly at 22° (mg/ml): 2582 in 20mM KCl/HCl buffer (pH 2); 364 in 20 mM phosphate buffer (pH 6).
pKa: pKa 8.5
Log P: Log P (octanol/water): 3.1
 
Derivative Type: Maleate
CAS Registry Number: 341031-54-7
Manufacturers' Codes: SU-11248
Trademarks: Sutent (Pfizer)
Molecular Formula: C22H27FN4O2.C4H6O5
Molecular Weight: 532.56
Percent Composition: C 58.64%, H 6.25%, F 3.57%, N 10.52%, O 21.03%
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.